A variety of T2D therapeutics bind to and activate the glucagon-like peptide 1 receptor (GLP1R), which acts through Gs-subfamily proteins to increase the catalytic activity of adenylyl cyclase and downstream cAMP production (3). Here, GLP1R is linked to type 2 diabetes mellitus.